Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 8/20 | 0.56 |
| ▸ | DDB1 | Q16531 | 7/20 | 0.56 |
| ▸ | DRD2 | P14416 | 3/20 | 0.33 |
| ▸ | DRD3 | P35462 | 3/20 | 0.33 |
| ▸ | DRD4 | P21917 | 2/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.32 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.32 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31639917 | 1.00 | CRBN (0.56) | CRBNDDB1DRD2DRD3DRD4 | |
| Hydrochloric Acid SCHEMBL25229932 | 0.99 | CRBN (0.55) | CRBNDDB1DRD2DRD3DRD4 | |
| SCHEMBL31639379 | 0.88 | DDB1 (0.47) | CRBNDDB1DRD2 | |
| SCHEMBL27179128 | 0.87 | CRBN (0.68) | CRBNDDB1DRD2DRD3DRD4 | |
| SCHEMBL30796887 | 0.87 | CRBN (0.68) | CRBNDDB1DRD2DRD3DRD4 | |
| SCHEMBL31640248 | 0.87 | CRBN (0.53) | CRBNDDB1 | |
| SCHEMBL31640142 | 0.87 | CRBN (0.53) | CRBNDDB1 | |
| SCHEMBL31639457 | 0.86 | DDB1 (0.47) | CRBNDDB1DRD2 | |
| SCHEMBL31639652 | 0.86 | CRBN (0.53) | CRBNDDB1 | |
| SCHEMBL31639758 | 0.85 | DDB1 (0.46) | CRBNDDB1ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | RET, HRAS, RBX1 | CRBN 10/4885DDB1 397/4885DRD2 3735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.